Amyotrophic lateral sclerosis (ALS), or Charcot disease, results in a progressive paralysis of the muscles which gradually makes it impossible to walk, eat, breathe or speak. In 2022, American health authorities chose to approve it on the basis of a first, smaller clinical trial.
Last month, Amylyx Pharmaceuticals announced the results of a trial carried out on 664 participants, showing that the treatment made no difference compared to a placebo. For patients already on treatment, around 3,900 in the United States, the company said it was offering to continue, free of charge.